drugset / Trial / NCT05067868
A Study of Replagal in Children and Adults With Fabry Disease in India
NaSingle-groupOpen-labelTreatment
Summary
The main aim of this study is to learn more about the safety profile of Replagal. Participants will receive Replagal every 2 weeks at the clinic for about 1 year.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2026-10-31
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Replagal | Protein / enzyme biologic | 0.2 mg/kg | Intravenous |